Department of Health Research signs MoU with
The MoU between Department of Health Research and NIHCE provides
the framework for strategic and technical cooperation between the
two countries with an aim to (i) bring modern
health technology to people by encouraging innovations;
(ii) translate these innovations into
products/processes by facilitating evaluation;
(iii) introduce the aforesaid innovations into
public health service. The two countries will also exchange
institutional expertise and experience on clinical trial
guidelines, quality standards, application of health technology
assessment and implementation of the decisions of the assessment
into clinical policy and practice. They will also explore the
opportunities for collaborative research projects in clinical
policy and practice.
PSA view - This is a good collaborative step
towards healthcare policy making and facilitating innovations. This
strategic and technical collaboration will benefit the Indian
healthcare system to a greater extent.
Ranbaxy under scanner of Drug Controller General of
Drug Controller General of India
("DCGI") Dr. G. N. Singh has said that
all approvals given to Ranbaxy drugs in India are in order and
there is no violation of Indian laws. However, he added that the
matters including grant of approvals in the past to Ranbaxy are
under scrutiny. He stated that the most important concern of DCGI
is to assure the safety and efficacy of the drugs in India and
that, if found guilty, action will be taken not just against
Ranbaxy but other companies as well. This is in the wake of recent
allegations being faced by Ranbaxy in the U.S for selling
adulterated drugs, originally manufactured at its plants in Dewas
(Madhya Pradesh) and Paonta Sahib (Himachal Pradesh).While the
company continues to assert that its drugs meet all regulatory
standards, a few hospitals and pharmacies like Mumbai-based Jaslok
Hospital has banned all medicines supply from Ranbaxy and
country-wide chemist chain Apollo Pharmacy has announced taking a
cautious stance on Ranbaxy drugs.
PSA View - Ranbaxy must make efforts to show
its commitment towards the highest standards of quality in its
operations and compliance. It should approach its investors and
consumers and assure them that the drugs are safe. Meanwhile, till
the time DCGI gives a clean chit, one should refrain from
prescribing/using Ranbaxy drugs.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
The food processing industry one of the largest industries in India is widely recognized as a 'sunrise industry' in India having huge potential for uplifting the agricultural economy, creation of large scale processed food manufacturing and food chain facilities, and the resultant generation of employment and export earnings.
One of the potential threats for manufacturing and sale of food/health supplements such as "Dietary food supplement", "Food supplements", "Nutritional supplements", "Health supplements", is its categorization in the category of "Food" or "Drugs", as there is a very thin line between "drugs/ medicines" and "nutritional supplements".
In its Cabinet Note in December, 2014, the Government of India proposed significant amendments to the Consolidated Foreign Direct Investment Policy, 2014 (''FDI Policy'') with respect to India's medical device industry.
Although in countries like the United States of America and New Zealand, drugs to be prescribed by medical practitioners are allowed to be advertised directly to consumers/patients and are regulated by the respective department of the Government in charge of drugs in the country, the same practice is not followed or encouraged in India.
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).